First
Trust Indxx Medical Devices ETF
(MDEV) |
1 | |
2 | |
3 | |
5 | |
6 | |
8 | |
9 | |
10 | |
11 | |
12 | |
18 |
Performance | ||||
|
|
|
Average
Annual
Total
Returns |
Cumulative
Total
Returns |
|
6
Months
Ended
9/30/23 |
1
Year
Ended
9/30/23 |
Inception
(6/22/21)
to
9/30/23 |
Inception
(6/22/21)
to
9/30/23 |
Fund
Performance |
|
|
|
|
NAV |
-11.62% |
10.62% |
-13.67% |
-28.41% |
Market
Price |
-11.44% |
10.88% |
-13.62% |
-28.33% |
Index
Performance |
|
|
|
|
Indxx
Global Medical Equipment Index |
-11.28% |
11.02% |
-13.14% |
-27.42% |
MSCI
World Health Care Index |
-0.40% |
10.88% |
0.67% |
1.54% |
MSCI
World Index |
3.13% |
21.95% |
-0.63% |
-1.44% |
Sector
Allocation |
%
of Total
Long-Term
Investments |
Health
Care |
100.0% |
Total |
100.0% |
Top
Ten Holdings |
%
of Total
Long-Term
Investments |
STERIS
PLC |
2.7% |
Koninklijke
Philips N.V. |
2.7 |
Intuitive
Surgical, Inc. |
2.5 |
Alcon,
Inc. |
2.5 |
Demant
A/S |
2.4 |
WuXi
AppTec Co., Ltd., Class H |
2.4 |
West
Pharmaceutical Services, Inc. |
2.4 |
Exact
Sciences Corp. |
2.4 |
Boston
Scientific Corp. |
2.4 |
Becton,
Dickinson & Co. |
2.3 |
Total |
24.7% |
![]() |
Performance
figures assume reinvestment of
all
distributions and do not reflect the
deduction
of taxes that a shareholder would
pay
on Fund distributions or the redemption
or
sale of Fund shares. An index is a statistical
composite
that tracks a specified financial
market
or sector. Unlike the Fund, the indices
do
not actually hold a portfolio of securities
and
therefore do not incur the expenses
incurred
by the Fund. These expenses
negatively
impact the performance of the
Fund.
The Fund’s past performance does not
predict
future performance. |
|
Beginning
Account
Value
April
1, 2023
|
Ending
Account
Value
September
30, 2023
|
Annualized
Expense
Ratio
Based
on the
Six-Month
Period
|
Expenses
Paid
During
the
Six-Month
Period
(a) |
First
Trust Indxx Medical Devices ETF (MDEV)
| ||||
Actual |
$1,000.00 |
$883.80 |
0.70% |
$3.30 |
Hypothetical
(5% return before expenses) |
$1,000.00 |
$1,021.50 |
0.70% |
$3.54 |
(a) |
Expenses
are equal to the annualized expense ratio as indicated in the table
multiplied by the average account value over the period
(April
1, 2023 through September 30, 2023), multiplied by 183/366 (to reflect the
six-month period). |
Shares |
Description |
Value | |||
COMMON
STOCKS (a) — 99.8% | |||||
|
Biotechnology
— 2.4%
|
| |||
625 |
Exact
Sciences Corp. (b) |
$42,637 | |||
|
Health
Care Equipment & Supplies
— 75.5%
|
| |||
401 |
Abbott
Laboratories |
38,837 | |||
579 |
Alcon,
Inc. (CHF) |
44,873 | |||
122 |
Align
Technology, Inc. (b) |
37,249 | |||
969 |
Baxter
International, Inc. |
36,570 | |||
163 |
Becton,
Dickinson & Co. |
42,140 | |||
391 |
BioMerieux
(EUR) |
37,957 | |||
806 |
Boston
Scientific Corp. (b) |
42,557 | |||
298 |
Carl
Zeiss Meditec AG (EUR) |
26,093 | |||
250 |
Cochlear
Ltd. (AUD) |
41,040 | |||
301 |
Coloplast
A/S, Class B (DKK) |
31,899 | |||
112 |
Cooper
(The) Cos., Inc. |
35,617 | |||
1,055 |
Demant
A/S (DKK) (b) |
43,759 | |||
1,014 |
DENTSPLY
SIRONA, Inc. |
34,638 | |||
361 |
Dexcom,
Inc. (b) |
33,681 | |||
495 |
Edwards
Lifesciences Corp. (b) |
34,294 | |||
2,537 |
Fisher
& Paykel Healthcare
Corp.,
Ltd. (NZD) |
32,814 | |||
507 |
GE
HealthCare Technologies,
Inc. |
34,496 | |||
496 |
Hologic,
Inc. (b) |
34,422 | |||
394 |
Hoya
Corp. (JPY) |
40,405 | |||
131 |
Insulet
Corp. (b) |
20,893 | |||
156 |
Intuitive
Surgical, Inc. (b) |
45,597 | |||
2,443 |
Koninklijke
Philips N.V.
(EUR)
(c) |
48,987 | |||
218 |
Masimo
Corp. (b) |
19,114 | |||
517 |
Medtronic
PLC |
40,512 | |||
2,240 |
Olympus
Corp. (JPY) |
29,102 | |||
150 |
Penumbra,
Inc. (b) |
36,286 | |||
186 |
ResMed,
Inc. |
27,504 | |||
161 |
Shockwave
Medical, Inc. (b) |
32,055 | |||
709 |
Siemens
Healthineers AG
(EUR)
(d) (e) |
35,980 | |||
2,772 |
Smith
& Nephew PLC (GBP) |
34,599 | |||
134 |
Sonova
Holding AG (CHF) |
31,870 | |||
224 |
STERIS
PLC |
49,150 | |||
271 |
Straumann
Holding AG (CHF) |
34,698 | |||
143 |
Stryker
Corp. |
39,078 | |||
578 |
Sysmex
Corp. (JPY) |
27,589 | |||
158 |
Teleflex,
Inc. |
31,033 | |||
1,430 |
Terumo
Corp. (JPY) |
37,922 | |||
315 |
Zimmer
Biomet Holdings, Inc. |
35,349 | |||
|
|
1,360,659 | |||
|
Health
Care Providers & Services
— 1.9%
|
| |||
1,159 |
Amplifon
S.p.A. (EUR) |
34,457 |
Shares |
Description |
Value | |||
| |||||
|
Life
Sciences Tools & Services —
20.0%
|
| |||
300 |
Agilent
Technologies, Inc. |
$33,546 | |||
87 |
Bio-Rad
Laboratories, Inc.,
Class
A (b) |
31,185 | |||
166 |
Danaher
Corp. |
41,185 | |||
26 |
Mettler-Toledo
International,
Inc.
(b) |
28,810 | |||
304 |
Revvity,
Inc. |
33,653 | |||
131 |
Sartorius
Stedim Biotech (EUR) |
31,301 | |||
71 |
Thermo
Fisher Scientific, Inc. |
35,938 | |||
136 |
Waters
Corp. (b) |
37,292 | |||
115 |
West
Pharmaceutical Services,
Inc. |
43,149 | |||
3,652 |
WuXi
AppTec Co., Ltd., Class H
(HKD)
(d) (e) |
43,721 | |||
|
|
359,780 | |||
| |||||
| |||||
|
Total
Investments — 99.8% |
1,797,533 | |||
|
(Cost
$2,475,839) |
| |||
|
Net
Other Assets and
Liabilities
— 0.2% |
4,499 | |||
|
Net
Assets — 100.0% |
$1,802,032 |
(a) |
Securities
are issued in U.S. dollars unless otherwise
indicated
in the security description. |
(b) |
Non-income
producing security. |
(c) |
Non-income
producing security which makes payment-in-
kind
(“PIK”) distributions. For the six months ended
September
30, 2023, the Fund received 104 PIK shares of
Koninklijke
Philips N.V. |
(d) |
This
security is exempt from registration upon resale under
Rule
144A of the Securities Act of 1933, as amended (the
“1933
Act”) and may be resold in transactions exempt from
registration,
normally to qualified institutional buyers. This
security
is not restricted on the foreign exchange where it
trades
freely without any additional registration. As such, it
does
not require the additional disclosure required of
restricted
securities. |
(e) |
This
security may be resold to qualified foreign investors and
foreign
institutional buyers under Regulation S of the 1933
Act. |
Abbreviations
throughout the Portfolio of Investments: | |
AUD |
–
Australian Dollar |
CHF |
–
Swiss Franc |
DKK |
–
Danish Krone |
EUR |
–
Euro |
GBP |
–
British Pound Sterling |
HKD |
–
Hong Kong Dollar |
JPY |
–
Japanese Yen |
NZD |
–
New Zealand Dollar |
Currency
Exposure Diversification |
%
of Total
Investments |
United
States Dollar |
61.7% |
Euro |
12.0 |
Japanese
Yen |
7.5 |
Swiss
Franc |
6.2 |
Danish
Krone |
4.2 |
Hong
Kong Dollar |
2.4 |
Australian
Dollar |
2.3 |
British
Pound Sterling |
1.9 |
New
Zealand Dollar |
1.8 |
Total |
100.0% |
|
Total
Value
at
9/30/2023 |
Level
1
Quoted
Prices |
Level
2
Significant
Observable
Inputs |
Level
3
Significant
Unobservable
Inputs |
Common
Stocks* |
$ 1,797,533 |
$ 1,797,533 |
$ — |
$ — |
* |
See
Portfolio of Investments for industry
breakout. |
ASSETS: |
|
Investments,
at value |
$1,797,533 |
Cash |
3,506 |
Receivables: |
|
Dividends |
1,711 |
Reclaims |
358 |
Total
Assets |
1,803,108 |
| |
LIABILITIES: |
|
Investment
advisory fees payable |
1,076 |
Total
Liabilities |
1,076 |
NET
ASSETS |
$1,802,032 |
| |
NET
ASSETS consist of: |
|
Paid-in
capital |
$2,835,932 |
Par
value |
1,000 |
Accumulated
distributable earnings (loss) |
(1,034,900
) |
NET
ASSETS |
$1,802,032 |
NET
ASSET VALUE,
per share |
$18.02 |
Number
of shares outstanding (unlimited number of shares authorized, par value
$0.01 per share) |
100,002 |
Investments,
at cost |
$2,475,839 |
INVESTMENT
INCOME: |
|
Dividends |
$7,182 |
Foreign
withholding tax |
(1,315
) |
Total
investment income |
5,867 |
| |
EXPENSES: |
|
Investment
advisory fees |
7,062 |
Total
expenses |
7,062 |
NET
INVESTMENT INCOME (LOSS) |
(1,195
) |
| |
NET
REALIZED AND UNREALIZED GAIN (LOSS): |
|
Net
realized gain (loss) on: |
|
Investments |
(161,540
) |
Foreign
currency transactions |
(162
) |
Net
realized gain (loss) |
(161,702
) |
Net
change in unrealized appreciation (depreciation) on: |
|
Investments |
(74,585
) |
Foreign
currency translation |
39 |
Net
change in unrealized appreciation (depreciation) |
(74,546
) |
NET
REALIZED AND UNREALIZED GAIN (LOSS) |
(236,248
) |
NET
INCREASE (DECREASE) IN NET ASSETS RESULTING FROM
OPERATIONS |
$(237,443
) |
|
Six
Months
Ended
9/30/2023
(Unaudited) |
Year
Ended
3/31/2023 |
OPERATIONS: |
|
|
Net
investment income (loss) |
$(1,195
) |
$729 |
Net
realized gain (loss) |
(161,702
) |
(176,064
) |
Net
change in unrealized appreciation (depreciation) |
(74,546
) |
(27,568
) |
Net
increase (decrease) in net assets resulting from
operations |
(237,443
) |
(202,903
) |
| ||
SHAREHOLDER
TRANSACTIONS: |
|
|
Proceeds
from shares sold |
— |
— |
Cost
of shares redeemed |
— |
— |
Net
increase (decrease) in net assets resulting from shareholder
transactions |
— |
— |
Total
increase (decrease) in net assets |
(237,443
) |
(202,903
) |
| ||
NET
ASSETS: |
|
|
Beginning
of period |
2,039,475 |
2,242,378 |
End
of period |
$1,802,032 |
$2,039,475 |
| ||
CHANGES
IN SHARES OUTSTANDING: |
|
|
Shares
outstanding, beginning of period |
100,002 |
100,002 |
Shares
sold |
— |
— |
Shares
redeemed |
— |
— |
Shares
outstanding, end of period |
100,002 |
100,002 |
|
Six
Months
Ended
9/30/2023
(Unaudited) |
Year
Ended
3/31/2023
|
Period
Ended
3/31/2022
(a) |
| |||
Net
asset value, beginning of period |
$20.39 |
$22.42 |
$25.17 |
Income
from investment operations: |
|
|
|
Net
investment income (loss)
|
(0.01
) (b) |
0.01 |
(0.46
) |
Net
realized and unrealized gain (loss) |
(2.36
) |
(2.04
) |
(2.29
) |
Total
from investment operations |
(2.37
) |
(2.03
) |
(2.75
) |
Net
asset value, end of period |
$18.02 |
$20.39 |
$22.42 |
Total
return
(c) |
(11.62
)% |
(9.05
)% |
(10.93
)% |
| |||
Ratios
to average net assets/supplemental data: |
|
|
|
Net
assets, end of period (in 000’s) |
$1,802 |
$2,039 |
$2,242 |
Ratio
of total expenses to average net assets
|
0.70
% (d) |
0.70
% |
0.70
% (d) |
Ratio
of net investment income (loss) to average net assets
|
(0.12
)% (d) |
0.04
% |
(0.36
)% (d) |
Portfolio
turnover rate (e) |
13
% |
22
% |
13
% |
(a) |
Inception
date is June 22, 2021, which is consistent with the commencement of
investment operations and is the date the initial creation units
were
established. |
(b) |
Based
on average shares outstanding. |
(c) |
Total
return is calculated assuming an initial investment made at the net asset
value at the beginning of the period, reinvestment of all
distributions
at net asset value during the period, and redemption at net asset value on
the last day of the period. The returns presented do not
reflect
the deduction of taxes that a shareholder would pay on Fund distributions
or the redemption or sale of Fund shares. Total return is
calculated
for the time period presented and is not annualized for periods of less
than a year. |
(d) |
Annualized. |
(e) |
Portfolio
turnover is calculated for the time period presented and is not annualized
for periods of less than a year and does not include securities
received
or delivered from processing creations or redemptions and in-kind
transactions. |
Undistributed
ordinary income |
$— |
Accumulated
capital and other gain (loss) |
(186,936
) |
Net
unrealized appreciation (depreciation) |
(610,521
) |
Tax
Cost |
Gross
Unrealized
Appreciation |
Gross
Unrealized
(Depreciation) |
Net
Unrealized
Appreciation
(Depreciation) |
$2,475,839 |
$22,174 |
$(700,480
) |
$(678,306
) |
Breakpoints |
|
Fund
net assets up to and including $2.5 billion |
0.7000
% |
Fund
net assets greater than $2.5 billion up to and including $5
billion |
0.6825
% |
Fund
net assets greater than $5 billion up to and including $7.5
billion |
0.6650
% |
Fund
net assets greater than $7.5 billion up to and including $10
billion |
0.6475
% |
Fund
net assets greater than $10 billion |
0.6300
% |